HUP0001661A2 - Kinolin-2-karbonsav-származék és alkalmazása serkentő hatású aminosavak antagonistájaként - Google Patents
Kinolin-2-karbonsav-származék és alkalmazása serkentő hatású aminosavak antagonistájakéntInfo
- Publication number
- HUP0001661A2 HUP0001661A2 HU0001661A HUP0001661A HUP0001661A2 HU P0001661 A2 HUP0001661 A2 HU P0001661A2 HU 0001661 A HU0001661 A HU 0001661A HU P0001661 A HUP0001661 A HU P0001661A HU P0001661 A2 HUP0001661 A2 HU P0001661A2
- Authority
- HU
- Hungary
- Prior art keywords
- carboxylic acid
- amino acids
- quinoline
- antagonist
- acid derivative
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 239000003257 excitatory amino acid Substances 0.000 title 1
- 230000002461 excitatory amino acid Effects 0.000 title 1
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical class C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 231100000189 neurotoxic Toxicity 0.000 abstract 1
- 230000002887 neurotoxic effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A találmány az (E)-4-(4-acetilaminő-fenil-karbamőil-metilén)-5,7-diklór-1,2,3,4-tetrahidrőkinlin-2-karbőnsav (+)-enantiőmerjére,illetve ennek sóira, előnyösen gyógyászatilag elfőgadható sóira, ilyenvegyületek előállítására, tővábbá a találmány szerinti vegyületeknekaz NMDA receptőrkőmplexre ható serkentő aminősavakat antagőnizálógyógyászati készítmények előállítására való alkalmazására vőnatkőzik.Említett hatásűkra tekintettel a találmány szerinti vegyületekfelhasználhatók többek között neűrőtőxikűs kárősődásők ésneűrődegeneratív megbetegedések kezelésére és megelőzésére. Atalálmány szerinti vegyületekre jellemző tővábbá, hőgy lényegébenmentesek a (-)-izőmertől, azaz az űtóbbi mennyisége kevesebb, mint10%. ŕ
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9706294.7A GB9706294D0 (en) | 1997-03-26 | 1997-03-26 | Heterocyclic compound |
| PCT/EP1998/001700 WO1998042673A1 (en) | 1997-03-26 | 1998-03-24 | Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0001661A2 true HUP0001661A2 (hu) | 2000-09-28 |
| HUP0001661A3 HUP0001661A3 (en) | 2001-12-28 |
Family
ID=10809909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0001661A HUP0001661A3 (en) | 1997-03-26 | 1998-03-24 | Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0971896A1 (hu) |
| JP (1) | JP2001518901A (hu) |
| KR (1) | KR20010005567A (hu) |
| CN (1) | CN1257482A (hu) |
| AP (1) | AP9901659A0 (hu) |
| AU (1) | AU731394B2 (hu) |
| BR (1) | BR9808424A (hu) |
| CA (1) | CA2284710A1 (hu) |
| EA (1) | EA199900755A1 (hu) |
| GB (1) | GB9706294D0 (hu) |
| HU (1) | HUP0001661A3 (hu) |
| ID (1) | ID24306A (hu) |
| IL (1) | IL131919A0 (hu) |
| IS (1) | IS5186A (hu) |
| NO (1) | NO994679L (hu) |
| NZ (1) | NZ337793A (hu) |
| PL (1) | PL335865A1 (hu) |
| TR (1) | TR199902315T2 (hu) |
| WO (1) | WO1998042673A1 (hu) |
| YU (1) | YU47699A (hu) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9917822D0 (en) * | 1999-07-29 | 1999-09-29 | Imperial College | Nmda antagonist |
| DE10132725A1 (de) | 2001-07-05 | 2006-08-03 | Grünenthal GmbH | Substituierte γ-Lactonverbindungen |
| DE10137487A1 (de) * | 2001-08-03 | 2003-03-27 | Gruenenthal Gmbh | Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate |
| DE10306202A1 (de) * | 2003-02-13 | 2004-08-26 | Grünenthal GmbH | Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen |
| JP4360891B2 (ja) | 2003-12-09 | 2009-11-11 | アルパイン株式会社 | 放送受信機能を備えた電子装置およびその装置における電子番組ガイドの表示方法 |
| JP4754566B2 (ja) * | 2005-07-22 | 2011-08-24 | 持田製薬株式会社 | 新規なヘテロシクリデンアセトアミド誘導体 |
| RU2451014C2 (ru) * | 2005-07-22 | 2012-05-20 | Мотида Фармасьютикал Ко., Лтд. | Новое производное гетероциклиден ацетамида |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| CA3067162A1 (en) | 2017-06-12 | 2018-12-20 | Glytech Llc. | Treatment of depression with nmda antagonists and d2/5ht2a or selective 5ht2a antagonists |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0386839B1 (en) * | 1989-03-08 | 1997-01-15 | Merck Sharp & Dohme Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
| AU708148B2 (en) * | 1995-09-29 | 1999-07-29 | Glaxo Wellcome S.P.A. | Tetrahydroquinolines as NMDA antagonists |
| GB9617305D0 (en) * | 1996-08-17 | 1996-09-25 | Glaxo Wellcome Spa | Heterocyclic compounds |
-
1997
- 1997-03-26 GB GBGB9706294.7A patent/GB9706294D0/en active Pending
-
1998
- 1998-03-24 WO PCT/EP1998/001700 patent/WO1998042673A1/en not_active Application Discontinuation
- 1998-03-24 EP EP98919133A patent/EP0971896A1/en not_active Withdrawn
- 1998-03-24 AP APAP/P/1999/001659A patent/AP9901659A0/en unknown
- 1998-03-24 EA EA199900755A patent/EA199900755A1/ru unknown
- 1998-03-24 CA CA002284710A patent/CA2284710A1/en not_active Abandoned
- 1998-03-24 YU YU47699A patent/YU47699A/sh unknown
- 1998-03-24 AU AU72094/98A patent/AU731394B2/en not_active Ceased
- 1998-03-24 KR KR1019997008630A patent/KR20010005567A/ko not_active Application Discontinuation
- 1998-03-24 CN CN98805302A patent/CN1257482A/zh active Pending
- 1998-03-24 HU HU0001661A patent/HUP0001661A3/hu unknown
- 1998-03-24 TR TR1999/02315T patent/TR199902315T2/xx unknown
- 1998-03-24 JP JP54323498A patent/JP2001518901A/ja active Pending
- 1998-03-24 NZ NZ337793A patent/NZ337793A/en unknown
- 1998-03-24 PL PL98335865A patent/PL335865A1/xx unknown
- 1998-03-24 ID IDW991108A patent/ID24306A/id unknown
- 1998-03-24 IL IL13191998A patent/IL131919A0/xx unknown
- 1998-03-24 BR BR9808424-0A patent/BR9808424A/pt not_active IP Right Cessation
-
1999
- 1999-09-17 IS IS5186A patent/IS5186A/is unknown
- 1999-09-24 NO NO994679A patent/NO994679L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001518901A (ja) | 2001-10-16 |
| EP0971896A1 (en) | 2000-01-19 |
| TR199902315T2 (xx) | 2000-05-22 |
| GB9706294D0 (en) | 1997-05-14 |
| NZ337793A (en) | 2001-02-23 |
| WO1998042673A1 (en) | 1998-10-01 |
| IL131919A0 (en) | 2001-03-19 |
| EA199900755A1 (ru) | 2000-08-28 |
| IS5186A (is) | 1999-09-17 |
| PL335865A1 (en) | 2000-05-22 |
| AU731394B2 (en) | 2001-03-29 |
| BR9808424A (pt) | 2000-05-23 |
| AU7209498A (en) | 1998-10-20 |
| KR20010005567A (ko) | 2001-01-15 |
| NO994679D0 (no) | 1999-09-24 |
| CN1257482A (zh) | 2000-06-21 |
| NO994679L (no) | 1999-11-24 |
| CA2284710A1 (en) | 1998-10-01 |
| AP9901659A0 (en) | 1999-09-30 |
| YU47699A (sh) | 2001-12-26 |
| HUP0001661A3 (en) | 2001-12-28 |
| ID24306A (id) | 2000-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20022264L (no) | Farmasoytisk blanding inneholdende tolterodin, samt anvendelse derav | |
| HUP0105027A2 (hu) | N-Heterociklusos vegyületek karbonsavszármazékai és karbonsav-izoszterei és alkalmazásuk | |
| UA48946C2 (uk) | Арилалкілдіазинони, спосіб їх одержання (варіанти), фармацевтичний склад, спосіб його одержання та спосіб лікування | |
| HUP0302114A2 (hu) | Eritropoietin-fehérjét tartalmazó folyékony gyógyászati készítmény, eljárás előállítására és alkalmazása | |
| HUP0204182A2 (hu) | Fumársavszármazékok használata mitokondriális betegségek kezelésére | |
| MX9604378A (es) | Amidas de acido quinolin-2-carboxilico sustituidas, su preparacion y su empleo como medicamentos, asi como productos intermedios. | |
| HUP0104088A2 (hu) | Késleltetett felszabadulású ranolazinkészítmények alkalmazása | |
| WO1997048391A3 (en) | Methods and compositions comprising r-ibuprofen | |
| HUP9603237A2 (hu) | (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzizotiazol-2-il)-butil]-amino-metil}-kromán kristályos hidrokloridja, eljárás előállítására és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP9802762A2 (hu) | Difenil-metilén-piperidin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk | |
| HUP0001661A2 (hu) | Kinolin-2-karbonsav-származék és alkalmazása serkentő hatású aminosavak antagonistájaként | |
| IT1265101B1 (it) | Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico | |
| MY115211A (en) | Novel amino acid derivatives, their preparation and use | |
| HUP9802121A2 (hu) | Imidazolinszármazékok, eljárás előállításukra és e vegyületeket tartalmazó gyógyszerkészítmények | |
| UA60352C2 (uk) | Синтетичні полісахариди та фармацевтична композиція, що їх містить | |
| HUP0100012A2 (hu) | Makrolid vegyületek alkalmazása rák és a makuláns elváltozások kezelésére | |
| MY108482A (en) | Compounds. | |
| HUP0003174A2 (hu) | 20(S)-Kamptotecin glikokonjugátumai, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
| CY1106105T1 (el) | Αλας μεγλουμινης ενος συγκεκριμενου κινολινοκαρβοξυλικου οξεως ενepγου επι των υποδοχεων nmda | |
| HUP9900978A2 (hu) | Dioszgenint tartalmazó készítmény | |
| IT1252185B (it) | Preparazioni farmaceutiche a liberazione programmata | |
| HUP9701284A2 (hu) | 2,3-Benzodiazepin-származékok felhasználása az endogén opioid rendszerrel összefüggő betegségek és állapotok kezelésére, és megelőzésére alkalmas gyógyászati készítmények előállítására | |
| HUP9802314A2 (hu) | Zeaxantin tiszta 3R-3'R sztereoizomerje makuláris degeneráció emberben való kezelésére | |
| AR001996A1 (es) | Compuestos para la inhibicion de la secrecion de acido gastrico, formulaciones farmaceuticas que lo comprenden, su uso para preparar unmedicamento y metodos de tratamiento o profilaxis para enfermedades inflamatorias gastrointestinales. | |
| ES2004693A6 (es) | Un procedimiento para la preparacion de una composicion farmaceutica solida administrable por via oral, que contiene vinburnina como principio activo. |